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Abstract. Peroxiredoxins (PRDXs) are a ubiquitously expressed 
family of small (22-27 κDa) non-seleno peroxidases that catalyze 
the peroxide reduction of H2O2, organic hydroperoxides and 
peroxynitrite. They are highly involved in the control of various 
physiological functions, including cell growth, differentiation, 
apoptosis, embryonic development, lipid metabolism, the 
immune response, as well as cellular homeostasis. Although the 
protective role of PRDXs in cardiovascular and neurological 
diseases is well established, their role in cancer remains 
controversial. Increasing evidence suggests the involvement 
of PRDXs in carcinogenesis and in the development of drug 
resistance. Numerous types of cancer cells, in fact, are 
characterized by an increase in reactive oxygen species (ROS) 
production, and often exhibit an altered redox environment 
compared with normal cells. The present review focuses on 
the complex association between oxidant balance and cancer, 
and it provides a brief account of the involvement of PRDXs in 
tumorigenesis and in the development of chemoresistance.
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1. Oxidative stress and the role of H2O2 as a second 
messenger
Life in an oxygen-rich environment has to deal with the 
danger of oxidative stress. Oxidative stress represents a 
biochemical state characterized by an excessive presence of 
free radicals and reactive metabolites potentially harmful for 
the organism (1,2). Free radicals are highly reactive chemical 
species, typically with a short half-life, consisting of an atom 
or a molecule containing one or more unpaired electrons. 
These electrons give a significant reactivity to the radical, 
making it able to bind to other radicals or subtract an elec-
tron from other molecules nearby. Reactive oxygen species 
(ROS) are the most important class of free radicals that 
are produced by organisms: Elevated levels result from an 
imbalance between the production of oxidants and their elim-
ination by the antioxidant system protecting the organism. 
The superoxide anion radical (O2=) is one of the best known 
ROS. Its metabolites, such as the hydroxyl radical (•OH) and 
hydrogen peroxide (H2O2), are very reactive (3). Reactive 
nitrogen species (RNS) are another family of free radicals 
(with antimicrobial action), derived from nitric oxide (•NO) 
and superoxide anion (O2=), that, acting together with ROS, 
can damage cells. Not surprisingly, in humans, associations 
between the level of oxidative stress and serious diseases, 
including diabetes mellitus, atherosclerosis, hypertension, 
inflammatory diseases, neurodegenerative disorders and 
cancer, are well known (1,2,4) (Fig. 1).
During normal cell metabolism, the production of ATP 
by aerobic respiration in mitochondria constantly produces 
ROS and RNS, such as the by-products of oxidative 
phosphorylation.
At low to moderate concentrations, ROS exert an 
important positive role in several physiological processes, 
including defense against infectious agents and cell 
signaling (5), although at high concentrations they are able 
to react with many cellular components, such as nucleic 
acids, proteins and lipids, causing DNA damage that escapes 
the DNA repair system. For this reason, their concentration 
needs to be strictly controlled. In numerous organisms, 
ROS, and especially H2O2, are signaling molecules able 
to cross the membranes, to function as second messengers 
inside the cell, and to induce specific signal transduction 
pathways. Furthermore, ROS and RNS are able to control the 
activity of enzymes by triggering several post-translational 
modifications, such as disulfide bond formation, thiol 
oxidation to sulfenic/sulfinic/sulfonic acid, glutathionylation, 
nitrosylation and carbonylation. Several studies have reported 
that cell stimulation by a variety of growth factors, cytokines 
and G-protein-coupled receptors generates intracellular 
H2O2, e.g. (6), so that it may be difficult to resolve whether 
the cell is being subjected to H2O2-dependent signaling 
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or to oxidative stress. Aerobic organisms are equipped 
with nonenzymatic (ascorbate, glutathione, tocopherol 
and carotenoid) or enzymatic [catalase (CAT), ascorbate 
peroxidase, superoxide dismutase (SOD), glutathione 
peroxidase (GPx) and peroxiredoxin] antioxidant systems to 
neutralize ROS and RNS in the cells and to finely control 
their concentrations.
2. A special class of antioxidant enzymes: The 
peroxiredoxins
One of the most important enzyme systems that, together 
with SOD, CAT and GPx, act in the defense against oxidative 
stress is the ῾peroxiredoxin’ (PRDX) family (7,8).
PRDXs have been identified in numerous organisms and 
constitute a ubiquitous family of thiol-dependent peroxidases, 
catalyzing the reduction of H2O2, alkyl hydroperoxides and 
peroxynitrite to water, the corresponding alcohol and nitrite, 
respectively (9-11), emerging as arguably the most impor-
tant and widespread peroxide and peroxynitrite scavenging 
enzymes in all of biology (12,13). Their role was long over-
shadowed by well-studied oxidative stress defense enzymes 
such as catalase and glutathione peroxidase, considered for a 
long time to be the major enzymes responsible for protecting 
cells against hydroperoxides.
Unlike heme-dependent catalase and the selenium-depen-
dent glutathione peroxidase, PRDXs do not require 
cofactors. They were identified approximately 27 years ago 
in yeast (14) and 25 years ago in mammals (15), and are 
functionally conserved in all three phylogenetic domains: 
Archaea, Bacteria and Eukaryota, stressing the importance 
of the existence of systems protecting against ROS for the 
evolution of living organisms (16) (Table I).
PRDXs have been classified into the following subgroups 
on the basis of functional site sequence similarity (17): 
Prx1/PRDX1, Prx5/PRDX5 and Prx6/PRDX6 (18). The 
phylogenetic distribution of PRDXs demonstrates the widest 
biological distribution for the Prx1/PRDX1 and Prx6/PRDX6 
subfamilies; Prx5/PRDX5 members are apparently lost in 
archaea (Table I).
PRDXs of different subgroups vary in their oligomeriza-
tion states, conformational flexibility, and certain secondary 
structural elements. In addition, most organisms possess 
multiple isoforms (19): In humans, for example, six different 
isoforms of PRDX are present (20), four PRDX1 subtypes, 
one PRDX5 subtype and one PRDX6 subtype.
PRDX1, PRDX2, PRDX3, PRDX5 and PRDX6 are local-
ized in the cytosol, in the mitochondria, in the nuclei and in 
the peroxisomes (21-23), whereas PRDX4 is mainly present 
in the endoplasmic reticulum, or it is secreted (24).
The catalytic activity of PRDXs is crucially dependent 
on a conserved peroxidatic Cys (Cp) residue contained within 
a universally conserved Pxxx(T/S)xxC active-site motif in 
the amino-terminal portion of the protein (17), which corre-
sponds to Cys-47 in yeast cytosolic thioredoxin peroxidase I 
(cTPx I) (15). Five out of six human PRDXs also contain 
an additional conserved Cys in the carboxy-terminal region, 
which corresponds to Cys‑170 in yeast thiol‑specific antioxi-
dant (TSA) (15), termed resolving cysteine (Cr). Depending 
on the PRDX, the Cr may be located within the same chain 
of Cp or in the chain of another subunit, therefore human 
PRDXs are classified into three classes: i) Typical 2‑Cys 
PRDXs, which include PRDX1-4, ii) atypical 2-Cys PRDX 
and PRDX5, and iii) 1-Cys PRDX and PRDX6 (25). The 
typical 2-Cys PRDXs are obligate homodimers containing 
two identical active sites, bringing the two redox-active 
cysteines (Cp and Cr) into close proximity (26). By contrast, 
atypical 2-Cys PRDXs form an intramolecular disulfide 
intermediate by reacting the amino-terminal sulfenic acid 
(Cys-47) with a carboxy-terminal Cys-SH (Cys-151) of the 
same molecule that is able to be reduced by thioredoxin (27).
PRDX6 is the only known mammalian member of 
the 1-Cys subgroup. The mechanism by which its sulfenic 
acid form is reduced has yet to be fully elucidated (27), but 
Monteiro et al (28) have unequivocally demonstrated that 
1-Cys PRDXs are reduced by ascorbate (Fig. 2).
Members of the Prx1/PRDX1 and Prx6/PRDX6 subfami-
lies dimerize using the ‘B interface’ (denoting the β-strand 
interactions) to form an extended 10 to 14-strand β-sheet (29) 
(Fig. 3), whereas members of the Prx5/PRDX5 subfamily 
Figure 1. Oxidative stress and human diseases. Oxidative stress plays a role in many pathological processes.
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Table I. PRDXs are functionally conserved in all three phylo-
genetic domains.a
 Identity (%)
 ---------------------------------
Species Gene symbol Protein DNA
H. sapiens PRDX1
  vs. P. troglodytes PRDX1 100.0 99.7
  vs. M. mulatta PRDX1 99.5 98.5
  vs. C. lupus PRDX1 99.0 93.3
  vs. B. taurus PRDX1 96.5  93.6
  vs. M. musculus Prdx1 95.5 90.8
  vs. R. norvegicus Prdx1 97.5 91.3
  vs. R. norvegicus Prdx1l1 97.0 91.3
  vs. G. gallus PRDX1 88.4 78.7
  vs. X. tropicalis LOC101731384 84.9 76.2
  vs. X. tropicalis Prdx1 84.9 76.0
  vs. D. rerio Prdx1 81.3 73.9
H. sapiens PRDX2
  vs. P. troglodytes PRDX2 100.0 99.8
  vs. M. mulatta PRDX2 100.0 98.1
  vs. C. lupus PRDX2 93.4 88.2
  vs. B. taurus PRDX2 91.2 87.4
  vs. M. musculus prdx2 93.4 88.2
  vs. R. norvegicus prdx2 93.4 87.0
  vs. X. tropicalis prdx3 79.6 70.7
  vs. X. tropicalis prdx2 77.5 72.4
  vs. D. rerio prdx2 76.6 72.8
  vs. D. melanogaster Jafrac1 71.3 67.4
  vs. A. gambiae TPX2 68.1 66.0
  vs. C. elegans prdx2 73.2 66.7
  vs. S. cerevisiae TSA1 66.8 61.1
  vs. S. pombe tpx1 68.8 60.8
  vs. A. thaliana 2Cys Prx B 63.8 61.2
  vs. A. thaliana AT3G11630 64.4 61.3
  vs. O. sativa Os02g0537700 62.2 61.5
H. sapiens PRDX3
  vs. P. troglodytes PRDX3 100.0 99.6
  vs. M. mulatta PRDX3 97.7 97.5
  vs. C. lupus PRDX3 91.4 88.2
  vs. B. taurus PRDX3 89.1 88.8
  vs. M. musculus Prdx3 86.3 84.2
  vs. R. norvegicus Prdx3 85.2 83.2
  vs. G. gallus PRDX3 79.2 71.7
  vs. M. mulatta LOC719764 99.2 97.8
  vs. D. rerio prdx3 75.4 66.8
  vs. D. melanogaster Prx3 64.5 61.7
  vs. A. gambiae TPX1 63.9 58.6
  vs. C. elegans prdx3 66.8 60.4
  vs. S. cerevisiae TSA2 57.3 57.1
  vs. K. lactis KLLA0B01628g 56.8 58.7
  vs. E. gossypii AGOS_AER312W 57.8 59.5
H. sapiens PRDX4
  vs. M. mulatta PRDX4 98.5 98.4
  vs. C. lupus PRDX4 93.0 89.2
  vs. B. taurus PRDX4 93.8 90.8
  vs. M. musculus Prdx4 95.0 89.1
Table I. Continued.
 Identity (%)
 --------------------------------
Species Gene symbol Protein DNA
  vs. R. norvegicus Prdx4 94.5 90.3
  vs. G. gallus PRDX4 91.9 81.6
  vs. X. tropicalis prdx4 93.6 81.1
  vs. D. rerio prdx4 88.7 74.8
  vs. D. melanogaster Jafrac2 71.0 64.4
  vs. A. gambiae TPX3 74.7 65.9
H. sapiens PRDX5
  vs. P. troglodytes PRDX5 99.5 99.7
  vs. B. taurus PRDX6 95.1 92.9
  vs. C. lupus PRDX5 85.5 84.9
  vs. B. taurus PRDX5 81.9 83.8
  vs. M. musculus Prdx5 87.2 86.1
  vs. R. norvegicus Prdx5 88.1 85.3
  vs. X. tropicalis prdx5 67.3 65.2
  vs. D. rerio prdx5 61.3 64.0
  vs. D. melanogaster Prdx5 59.5 62.4
  vs. A. gambiae AgaP_AGAP 60.0 60.9
 001325
  vs. K. lactis KLLA0A07271g 39.3 46.8
  vs. E. gossypii AGOS_ADL154C 40.5 48.4
  vs. S. pombe SPCC330.06c 35.3 42.7
  vs. M. oryzae MGG_00860 44.4 53.0
  vs. N. crassa NCU06880 44.1 52.8
  vs. A. thaliana AT1G60740 42.7 49.7
  vs. A. thaliana TPX1 43.9 50.5
  vs. A. thaliana TPX2 42.7 49.7
  vs. O. sativa Os01g0675100 44.0 49.9
H. sapiens PRDX6
  vs. P. troglodytes PRDX6 100.0 99.7
  vs. M. mulatta PRDX6 98.7 98.4
  vs. C. lupus PRDX6 92.9 91.5
  vs. M. musculus Prdx6 89.7 87.4
  vs. R. norvegicus Prdx6 91.5 88.8
  vs. G. gallus PRDX6 86.4 78.0
  vs. X. tropicalis prdx6 76.9 71.0
  vs. D. rerio prdx6 73.6 67.3
  vs. D. melanogaster Prx6005 61.0 58.9
  vs. A. gambiae TPX5 60.2 59.7
  vs. C. elegans prdx6 52.4 55.6
  vs. S. cerevisiae PRX1 51.0 54.8
  vs. K. lactis KLLA0E20285g 48.6 54.6
  vs. E. gossypii AGOS_AGR368W 50.5 55.4
  vs. M. oryzae MGG_08256 53.5 58.1
  vs. N. crassa NCU06031 53.3 58.7
  vs. A. thaliana PER1 52.6 55.8
  vs. O. sativa Os07g0638300 53.5 59.3
  vs. O. sativa Os07g0638400 53.9 56.5
aHomologs of the PRDX genes are listed in the Table. In the figure 
the Pairwise Alignment Scores and evolutionary distances have been 
reported (http://www.ncbi.nlm.nih.gov/gene/). PRDX, peroxire-
doxin; TPX, thiol peroxidase.
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typically dimerize and associate across the ‘A interface’ 
(denoting either ‘alternate’ or ‘ancestral’). In addition, a large 
number of PRDXs that form dimers across their B interface 
can show a further redox-sensitive dependent oligomeriza-
tion to form octamers, decamers or dodecamers across their 
A interface (19).
Typical 2-Cys PRDXs (PRDX1-4) form decamers or 
dodecamers in the reduced or hyperoxidized state, acquiring 
the ability to exercise other functions as chaperones, binding 
partners, enzyme activators and/or redox sensors, while the 
oxidized form is preferentially present as dimers (30) (Fig. 3). 
Atypical 2-Cys PRDXs are able to undergo protein-protein 
interactions with functional implications, although their 
level of polymerization is less compared with that of typical 
2-Cys PRDXs.
By contrast, 1-Cys PRDXs are not able to form decamers, 
and this is probably the reason why they serve mainly an 
antioxidant function rather than a molecular chaperone func-
tion, despite their enzymatic mechanism being very similar 
to that of 2-Cys PRDXs (31). Concerning the catalytic func-
tion, PRDXs tune the sensitivity to hyperoxidation switching 
from a fully folded (FF) conformation, in which Cp can react 
with the peroxide, to a locally unfolded (LU) conformation, 
in which the Cp is exposed and can form a disulfide bridge 
with the Cr (Fig. 4).
PRDXs are highly involved in the control of cellular 
physiological functions, including growth, differentiation, 
apoptosis, embryonic development, lipid metabolism, the 
immune response, as well in the maintenance of cellular 
homeostasis (32) (Fig. 5). Over the course of the last few years, 
a large body of evidence has suggested their involvement in 
carcinogenesis and in the development of drug resistance. This 
review focuses on the complex relationships between oxidant 
balance and cancer, and it provides a brief account of the 
involvement of PRDXs in tumorigenesis and in the develop-
ment of chemoresistance.
3. ROS stress in cancer cells
ROS, such as the superoxide radical, the hydroxyl radical and 
H2O2 or RNS, such as peroxynitrites and nitrogen oxides, are 
toxic metabolic secondary products that pose a significant 
threat by damaging DNA, lipids, proteins and other macro-
molecules (33). Controlling their cellular levels is essential for 
proper function. Nanomolar amounts of ROS are able to act 
as potent mitogens, regulating cell growth and angiogenesis. 
High levels of ROS may be harmful, causing damage and 
driving signaling pathways involved in proliferation arrest, 
or even in cell death (34). Several studies have implicated 
an increase of ROS in carcinogenesis due to a loss of proper 
redox control (35-39). Aberrant ROS levels are able to drive 
cancer initiation and progression. In general, the activity of 
ROS on carcinogenesis depends on their mutagenic potential. 
Their contribution to cancer progression and metastases is 
mainly due to their ability to affecting anchorage-independent 
cell growth (40,41), the epithelial-to-mesenchymal transi-
tion (EMT) (42), de novo angiogenesis (43,44) and apoptosis 
through the modulation of the phosphoinositide 3-kinase 
(PI3-kinase)/Akt pathway (41).
Moreover, the tendency of cancer cells to undergo profound 
changes in their own intrinsic metabolism (Warburg metabolic 
reprogramming), characterized by increased activity in aerobic 
glycolysis and by lipid metabolism deregulation, is also largely 
modulated by oxidative stress. Therefore, ROS may promote 
numerous aspects of tumor onset and progression towards a 
malignant phenotype (45-47). Nevertheless, it should not be 
overlook that high levels of ROS can be lethal for the cancer 
cells. This could be one of the reasons why cancer cells, in 
Figure 2. Mechanisms of the three PRDX subtypes. In typical 2-Cys PRDXs, the main cysteine residue (Cp) reacts with the residue Cr on the second subunit 
of the dimer. In atypical 2-Cys PRDXs, the oxidized Cp reacts with the Cr residue located in the same molecule. In 1-Cys PRDXs, the Cp residue generates 
sulfenic acid and is regenerated directly through donation of an electron to the thiol form in presence of ascorbate. Cyp, cyclophilin; Grx, glutaredoxin; GSH, 
reduced glutathione; ROOH, peroxide; Cp, peroxidatic Cys; Cr, resolving cysteine; Trx, thioredoxin.
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order to defend themselves, potentiate their antioxidant 
capacity (48,49).
4. PRDXs in tumorigenesis
Cells are endowed with several overlapping peroxide-degrading 
systems, the relative importance of which is a matter of debate. 
PRDXs are a fascinating group of thiol-dependent peroxi-
dases that, under physiological conditions, are responsible for 
divergent functions, such as protecting cells against oxidative 
DNA damage and genomic instability, regulating cell signaling 
associated with H2O2, and influencing cell differentiation and 
proliferation, immune responses and apoptosis (50) (Fig. 6). A 
number of studies have demonstrated that cancer cells exhibit 
an increased production of ROS, in part caused by a loss in 
proper redox control (35,36-39). Therefore, over the course of 
the last few years, much attention has been paid to exploring the 
role of PRDXs in cancerogenesis. Increased or decreased levels 
of PRDXs have been demonstrated in many human cancers. 
Studies performed in vitro or in vivo models have demonstrated 
that overexpression of PRDXs may either inhibit cancer develop-
ment or promote cancer growth (48), depending on the specific 
PRDX family member and on the cancer context.
In the following chapters, the most recent findings regarding 
the dual action of PRDXs in tumorigenesis are reviewed and 
discussed. Table II summarizes different types of cancer in 
which the expression of an individual member of the PRDX 
family is altered.
PRDX1: Dual effect in cancerogenesis. Amongst the PRDX 
family members, PRDX1 possess the widest cellular distribu-
tion and show the highest abundance in various tissues (51). 
Its cellular expression is controlled at the transcriptional 
level by nuclear factor (erythroid-derived 2)-related factor 2 
(NRF2) (52), and at the post-transcriptional level, through 
degradation and deadenylation/polyadenylation processes (53).
PRDX1 as a tumor suppressor. A tumor suppressor func-
tion of PRDX1 was first demonstrated in a knockout‑mouse 
model, where its deficiency generated mice suffering from 
hemolytic anemia and multiple tumors, including mammary 
carcinomas (54-56). These studies suggested that the tumor 
suppressive effects of PRDX1 were mediated by a reduction 
of c-Myc transcriptional activity (55) or of phosphatase and 
tensin homolog (PTEN/AKT) activity (56). In particular, 
PRDX1 exerts its protective effect by oxidation of the Cys 
Figure 3. Quaternary structure of PRDXs. (A) A-type dimers or B-type dimers. Certain components of the PRDX1 and PRDX6 subfamilies form a decameric 
structure through the interaction of five B‑type dimers via the A‑type dimer interface (A‑type dimer colored in purple/blue; B‑type dimer colored in blue/light 
blue). (B) The model of typical 2-Cys PRDX oligomerization and function: Different factors induce oligomerization of the dimers to hexa-, octa-, decamers 
or higher-order aggregates that are able to function as a peroxidase. Oxidation leads to the breakdown of the decamers, whereas hyperoxidation stabilizes the 
oligomer. Oxidized decamers can be reversed by sulfiredoxin (Srx) reduction (167). Hyperoxidized decamers are stable HMW complexes with chaperone‑like 
activity. LMW, low molecular weight; HMW, high-molecular-weight; PRDX, peroxiredoxin. 
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residue located within the active site of PTEN phosphatase, 
thereby reducing the predisposition of PRDX1‑deficient mice 
to develop Ras-induced mammary tumors (56).
In breast cancer (estrogen-receptor-positive cases), PRDX1 
prevents oxidative stress-mediated estrogen receptor α 
reduction. Its overexpression in these cancer tissues may be 
considered as a biomarker of favorable prognosis (57). In lung 
cancer, the tumor suppressant effect is mediated by the modula-
tion of the ROS-mediated activation of the K-Ras/extracellular 
signal-regulated kinase (ERK) pathway (58). Similarly, in 
Figure 4. Catalytic mechanism of typical 2-Cys PRDXa. (A) PRDXs switch from an FF conformation, in which Cp reacts with the peroxide, to an LU conforma-
tion, in which the Cp is exposed and forms a disulfide bridge with the Cr residue. The thiol groups are converted into sulfenic acid (‑S‑OH) and form disulfide 
bonds with other thiol groups (-SS-) (oxidized status-LU conformation). At high peroxide concentrations, the sulfenic acid intermediate is overoxidized to 
sulfinic acid (‑SOOH) or even sulfonic acid (‑SOOOH), causing the inactivation of the enzyme (hyperoxidized status). (B) Stereo‑view of the interpolated 
structural changes shown in rainbow colors between the FF (blue) and LU (red) conformations for a representative of Prx1 subfamily (upper) and Prx5 
subfamily (lower). PRDX, peroxiredoxin; Srx1 sulfiredoxin 1, Trx, thioredoxin; TrxR, thioredoxin reductase; FF, fully folded; LU, locally unfolded.
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human acute myeloid leukemia (AML), PRDX1 promotes the 
reactivation of the protein tyrosine phosphatase DEP-1, a tumor 
suppressor that counteracts the action of the transforming 
kinase, FLT3 ITD (59).
PRDX1 as a tumor promoter. The tumor-promoting function 
of PRDX1 has been demonstrated in numerous types of human 
cancer, and appears to be mediated through its interaction with 
several cancer-associated signal pathways. An increased level 
of PRDX1 has been described in lung cancer (60), in bladder 
cancer (61), in ovarian carcinoma (62), in aggressive esophageal 
squamous carcinomas (63), in hilar cholangiocarcinoma (64), 
in liver cancer (65), in pancreatic cancer (66), in mesothe-
lioma (67) and in glioblastoma (68). In prostate cancer, PRDX1 
overexpression induces tumor growth and tumor progression 
through the Toll-like receptor 4 (TLR4)-dependent regulation 
Figure 5. WordCloud for PRDXs. The WordCloud representation shows the majority information about the PRDX family (see http://www.maayanlab.net/G2W/
help.php). PRDX, peroxiredoxin. 
Figure 6. Antioxidants: a ‘double‑edged sword’ in tumorigenesis. Antioxidants are a double‑edged sword in tumorigenesis, and may be involved in reduction 
of the levels or reactive oxygen species (beneficial effect) or in accelerating tumor formation, inhibiting senescence or apoptotic processes (harmful effects).
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of tumor vasculature, increasing the expression of the vascular 
endothelial growth factor (VEGF) (69). In certain lung cancer 
cellular models, it has become well established that the 
pro-oncogenic role of PRDX1 is mediated by the activation 
of c-Jun and AP-1 (70), and that the transforming growth 
factor β1 (TGFβ1)-induced EMT is caused by direct inhibi-
tion of E-cadherin expression (71). In addition, PRDX1 may 
exerts its tumor-promoting function by affecting intracellular 
signaling pathways that affect apoptosis. In thyroid cancer 
cells, it inhibits apoptosis through the inhibition of apoptosis 
signal-regulating kinase 1 (ASK1) activity (72), whereas in 
human hepatoma it suppresses the redox-dependent activation 
of caspases, inducing tumor necrosis factor-α (TNFα)-related 
apoptosis-inducing ligand (TRAIL) resistance (73).
Decreased PRDX1 levels in papillary thyroid carcinomas 
(PTCs) (74) correlate with the presence of the BRAF V600E 
mutation and of lymph node metastasis, suggesting that 
PRDX1 reduction may be caused by mutated BRAF, and 
this is associated with a more aggressive clinical outcome of 
PTCs (75).
PRDX2: Dual effect in cancerogenesis. PRDX2 is another 
member of the typical 2-Cys subgroup, and it is mainly 
present in the cytosol (76). In red blood cells (RBCs), the 
oxidation-reduction cycle of PRDX2 correlates with a robust 
temperature-entrainable and temperature-compensated 
circadian rhythm, the oscillations of which result in circadian 
rhythm-dependent oligomerization of PRDX2 (77). Notably, 
the fluctuations in levels of hyperoxidized PRDX2 are not 
affected at the transcriptional level, considering the absence 
of a nucleus in the RBCs (77); neither are they controlled by 
sulfiredoxin (Srx), but are rather controlled by hemoglobin 
autoxidation and the 20S proteasome (78). Circadian rhythms 
are highly conserved time-tracking systems regulating 
important biological processes at the systemic and the cellular 
level (76). Interestingly, it has been recently demonstrated that 
the nuclear levels of PRDX2 oscillate rhythmically over two 
entire 24-h long cycles in HaCaT keratinocytes, contributing 
to the regulation of the redox balance of human keratinocytes. 
These findings open new perspectives for an understanding of 
circadian-pathophysiological processes in the skin (79). It is 
not yet clear whether the PRDXs are essential for circadian 
rhythmicity, although it is evident that their deletion has gener-
ally deleterious cellular consequences (77).
PRDX2 is one of the most efficient intracellular H2O2 scav-
engers compared with the other antioxidants (80). Depending 
on its oxidized or hyperoxidized status, PRDX2 forms 
homodimers or oligomers, functioning as an H2O2 scavenger 
or as a chaperone, respectively (81). Its expression is regulated 
by ROS induction in a PTEN-dependent manner (82), and at 
the transcriptional level by Hand1/Hand2 factor (83) or by 
the extensive methylation of CpG islands in the promoter 
region (84).
PRDX2 as a tumor suppressor. Depending on the tumor type 
and the stage of tumor progression, PRDX2 may exhibit strong 
Table II. Differential expression of PRDX family members in tumor types.a
 
PRDX family member Expression levels in different tumor types Refs.
 
PRDX1 Increased in: Lung cancer, bladder cancer, ovarian carcinoma, aggressive (60-67,142)
 esophageal squamous carcinomas, mesothelioma, glioblastoma, hilar
 cholangiocarcinoma, esophageal squamous cell carcinoma, liver cancer and 
 pancreatic cancer
 Decreased in: Thyroid tumors (PTCs) (74,75)
PRDX2 Increased in: Colorectal cancers, B cell-derived primary lymphoma cells, (87-92,94)
 vaginal carcinoma, cervical cancer, ovarian cancer, prostate cancer,
 esophageal cancer and B-cell-derived primary lymphoma cells 
 Decreased in: Melanoma (85)
PRDX3 Increased in: Hepatocellular carcinomas, malignant mesothelioma, breast (67,102-106)
 carcinoma, prostate cancer, cervical carcinoma and lung cancer 
PRDX4 Increased in: Pancreatic cancer, prostate cancer, oral cavity squamous cell (70,90,114,116-119)
 carcinoma, colorectal cancer, breast cancer, ovarian cancer and lung cancer 
 Decreased in: Pancreatic cancer and acute promyelocytic leukemia (113,121)
PRDX5 Increased in: Aggressive Hodgkin lymphomas, malignant mesothelioma, (67,87,103,127,128)
 breast carcinoma, ovarian carcinoma and thyroid cancer 
 Decreased in: Adrenocortical carcinoma (129)
PRDX6 Increased in: Breast cancer, malignant mesothelioma, bladder cancer, (61,67,87,141-146)
 esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, cancer of
 the gingivo-buccal area and lymphoma
 Decreased in: Thyroid tumors (75,149)
aA summary is provided of the different types of cancer in which the expression of individual members of the PRDX family is up or downregu-
lated. PRDX, peroxiredoxin; PTCs, papillary thyroid carcinomas.
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tumor-suppressive or tumor-promoting functions. A decreased 
expression of PRDX2 has been demonstrated in only a few 
types of cancer, among which are the melanomas. The function 
of PRDX2 in melanoma cell growth and metastasis has not yet 
been fully elucidated. To date, it has been demonstrated, both 
in vitro in melanoma cell lines and in vivo in metastatic mela-
noma models, that a downregulation of PRDX2 correlates with 
increased proliferative and migratory activities, and with the 
acquisition of a metastatic potential. In particular, it appears 
that the PRX2-mediated signaling pathway for suppression 
of melanoma metastasis involves a synergistic collaboration 
of the processes of ERK-dependent E-cadherin expression 
and the Src-dependent retention of β-catenin in the adherens 
junctions (85). In a colorectal cancer (CRC) cellular model, 
PRDX2 inhibits TGFβ1-induced EMT, reducing the invasive 
phenotype through the modulation of the transcription factors, 
Twist1, Snail, ZEB1 and ZEB2 (86).
PRDX2 as a tumor promoter. Over the course of the last few 
years, a number of studies, instead, have revealed that PRDX2 
is increased in various human malignancies, suggesting a 
possible role for PRDX2 as a tumor promoter. High levels 
of PRDX2 and 4 were observed in ovarian borderline cancer 
compared with the other benign ovarian lesions, allowing a 
hypothesis to be made for the potential use of these in deter-
mining a differential diagnosis between benign and borderline 
epithelial ovarian tumors (87). Elevated expression levels of 
PRDX2 have also been found in vaginal carcinoma (88), in 
cervical cancer (89), in prostate cancer (90), in esophageal 
cancer (91) and, more recently, in B cell-derived primary 
lymphoma cells (92). In breast cancer, PRDX2 works like a 
‘metabolic adaptor’ driver protein that specifically induces 
the selective growth of metastatic cells in the lung by 
protecting them against oxidative stress (93). The dual action 
of PRDX2 in tumorigenesis has been demonstrated in a CRC 
model. Lu et al (94), in contrast with what was reported by 
Feng et al (86), demonstrated that PRDX2 overexpression in 
CRC tissues was strongly correlated with a more aggressive 
cancer behavior, tumor metastasis and the tumor-node-metas-
tasis (TNM) stage, indicating a possible role for PRDX2 in 
CRC progression. Taken together, these data suggest that the 
mechanism by which PRDX2 exerts its oncogenic action is 
still poorly understood, and further studies are required.
PRDX3: Tumor‑promoting effects. PRDX3 is a mitochondrial 
member of the antioxidant family of thioredoxin peroxidases 
that uses mitochondrial thioredoxin 2 (Trx2) as a source of 
reducing equivalents to scavenge hydrogen peroxide (95). 
Its specific localization to the mitochondria suggests that 
PRDX3, together with its mitochondrion-specific electron 
suppliers, Trx2 and Trx reductase 2 (TrxR2), may provide a 
primary line of defense against H2O2 produced by the mito-
chondrial respiratory chain (96). PRDX3 is highly sensitive to 
the oxidative state. The regulation of its expression involves 
sirtuin 1 (SIRT1), a class III histone deacetylase that is not 
cell‑type‑specific, in bovine aortic endothelial cells. SIRT1 
positively controls PRDX3 expression by an enhancement 
of the formation of the PGC‑1α/FoxO3a transcriptional 
complex (97). Depending on the cancer type, the regulation 
of PRDX3 expression may be mediated by different factors. 
In colon cancer stem cells (CSCs), the forkhead box protein 1, 
FOXM1, activates transcription of PRDX3 and the expression 
of CD133 (98). In medulloblastoma tumor tissue samples and 
cell lines, the level of the microRNA, miR-383, is a modu-
lator of PRDX3 expression (99), whereas in human prostate 
cancer cells, miR-23b directly regulates PRDX3 expression 
under normal and hypoxic conditions (100). Finally, in von 
Hippel‑Lindau (VHL)‑deficient clear cell renal cell carcinoma 
(CCRCC), the transcription factor, hypoxia-inducible factor 1 
(HIF-1), downregulates the level of PRDX3 (101).
A high level of PRDX3 expression has been reported 
in hepatocellular carcinomas (102), in malignant mesothe-
lioma (67), in breast carcinoma (103), in prostate cancer (104), 
in lung cancer (105) and in cervical carcinoma (106). All these 
studies have demonstrated that PRDX3 overexpression in 
cancer cells correlates with a more aggressive phenotype.
PRDX4: Tumor‑promoting effects. PRDX4 is another member 
of the typical 2-Cys PRDX family, homologous with other 
typical 2-Cys PRDXs, such as PRDX1 and PRDX2, which 
share the same catalytic mechanism. It is located predomi-
nantly in the endoplasmic reticulum (ER) and extracellular 
spaces, with the highest expression occurring in the pancreas, 
liver and heart, and lowest expression in blood leukocytes and 
the brain (107). A distinctive hydrophobic amino-terminus in 
PRDX4 functions as a signal sequence involved in the process 
of secretion from the cells (108). No solid evidence is avail-
able regarding the role of extracellular PRDX4 as a biomarker 
in certain types of disease (24). It has been suggested that 
the secretable form of PRDX4 may be involved in the 
interactions between carcinoma cells and the extracellular 
environment (109).
PRDX4 controls oxidative stress by reducing H2O2 to 
water in a thiol-dependent catalytic cycle. In addition, it 
has an important chaperone function, operating by means 
of a versatile mechanism that allows it to switch from 
redox‑dependent and reversibly convertible, disulfide‑linked 
homodimers to higher-order multimers, which enables the 
interaction with binding partners, including stress-responsive 
kinases, membrane proteins and immune modulators (110). As 
a chaperone protein, it cooperates with the protein disulfide 
isomerase (PDI), a key foldase and chaperone at the ER level, 
mediating the oxidative folding of various ER proteins (111). 
The PRDX4/PDI system was established to be a new oxidative 
folding pathway, working in parallel with the ER oxidore-
ductin 1 (ERO1)/PDI pathway (24).
As described above for the other PRDXs, modifications in 
PRDX4 levels have been associated with invasion, recurrence, 
prognosis, and other characteristics of cancer (112).
In pancreatic cancer, several reports have described the 
downregulation or upregulation of PRDX4 (113,114), although 
it is not yet clear whether the PRDX4 expression level may 
be considered to be a cause or an effect of pancreatic cancer. 
PRDX4 is overexpressed in prostate cancer (90), where it 
enhances the rate of cell proliferation (115). In other types 
of epithelial cancers, such as oral cavity squamous cell 
carcinoma (116), breast cancer (117), ovarian cancer (118), 
CRC (119) or lung cancer (70), overexpression of PRDX4 
correlates with the metastatic potential. In particular, in lung 
cancer A549 cells, the Srx-PRDX4 complex significantly 
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contributes to the maintenance of anchorage-independent 
colony formation, cell migration and invasion (120). It is 
noteworthy that PRDX4 is overexpressed in the majority of 
cancers where Srx is also overexpressed (113), contributing 
to cell proliferation by the activation of the RAS-RAF-MEK 
signaling pathway (120). On the other hand, its marked down-
regulation has been reported in acute promyelocytic leukemia 
(APL) (121).
PRDX5: Tumor‑promoting effects. PRDX5 was the last 
member to be identified among the six mammalian PRDXs. 
It is the unique atypical 2-Cys PRDX in mammals, widely 
expressed in tissues at different levels, with a large subcellular 
distribution including the mitochondria, the peroxisomes, the 
cytosol and the nucleus (22). PRDX5 is a thioredoxin peroxi-
dase that acts mainly by reducing alkyl hydroperoxides and 
peroxynitrite via cytosolic or mitochondrial thioredoxins. Its 
crystal structures highlight the unconventional enzymatic 
mechanism, involving two catalytic Cys residues that provide 
an opportunity for reaction with an additional molecule of 
H2O2, leading to overoxidation of Cp (122). PRDX5 is a cyto-
protective antioxidant enzyme rather than a redox sensor, able 
to act against endogenous or exogenous peroxide attacks. Its 
overexpression in different subcellular compartments defends 
cells against death provoked by nitro-oxidative stresses, while 
its silencing makes the cells more susceptible to oxidative 
damage and apoptosis (122). It is constitutively expressed at 
a high level in different mammalian cell lines and normal 
tissues, but the specific transcription factors involved in the 
regulation of its expression have not yet been completely 
identified. It is known that transcription factors such as AP‑1, 
nuclear factor-κB (NF-κB), antioxidant response element 
(ARE), insulin response element (InRE), glucocorticoid 
response element (GRE) (123), and also c-Myc (124), may 
directly modulate PRDX5 expression by interacting with 
putative responsive elements in the 5'‑flanking region of the 
gene. Other transcription factors, such as nuclear respiratory 
factor 1 (NRF-1) and nuclear respiratory factor 2 (NRF-2; 
GABPA), involved in the response of mammalian cells 
to oxidative stress and in the biogenesis of mitochondria, 
are also able to modulate PRDX5 expression in an indirect 
way (123,125). c-Myc not only directly controls PRDX5 
transcription, but also contributes in the maintenance of ROS 
homeostasis through its ability to selectively induce the tran-
scription of specific PRDXs when the function of one of them 
is compromised (124). Up- or downregulation of PRDX5 has 
been reported in different types of cancer. An upregulation of 
transcriptional activity of PRDX5, mediated by E-twenty-six 
transcription factor 1 and 2 (Ets1/2) and high-mobility-group 
protein B1 (HMGB1), has been described in human prostate 
and epidermoid cancer cells exposed to H2O2 or hypoxia (126). 
Increased levels of PRDX5 have been reported in aggressive 
Hodgkin's lymphomas (127), in malignant mesothelioma (67), 
in breast carcinoma (103), in ovarian carcinoma (87) and in 
thyroid cancer (128). Reduced levels of PRDX5 expression 
have been described only in adrenocortical carcinoma (129).
PRDX6: Tumor‑promoting effects. PRDX6 is the prototype 
and the only mammalian 1-Cys member of the PRDX family. 
Homologous 1-Cys proteins are widely distributed throughout 
all kingdoms, and they have been described in archaea, 
bacteria, parasites, yeast, insects, mollusks, amphibians, birds 
and other orders (130) (Table I). Although PRDX6 shares 
structural and functional properties with other members of 
the family, it has important and unique characteristics: It has 
a single conserved Cys residue causing a different catalytic 
cycle, and it uses glutathione (GSH) instead of thioredoxin 
as the physiological reductant. Furthermore, PRDX6 is able 
to bind and reduce phospholipid hydroperoxides, serving an 
important role in the repair of membrane damage caused by 
oxidative stress and, finally, it is a bifunctional enzyme with 
both phospholipase A2 (PLA2) activity and peroxidase func-
tion (130). Its catalytic Cys residue is buried at the base of 
a narrow pocket, differently from the other PRDXs, which 
renders PRDX6 unable to dimerize through disulfide forma-
tion in the native configuration, although it can homodimerize 
and multimerize through hydrophobic interactions (131).
PRDX6 has a widespread distribution in all organs, and 
essentially in all cell types (130). Its expression is regu-
lated by the mainly redox-active regulators, such as Nrf2, 
Nrf3 (132,133), NF-κB (134), Sp1 (135), c-Jun, c-Myc (130) and 
HSF1 (136), which are able to interact with the ARE and the 
putative GRE localized in the PRDX6 gene promoter region. 
PRDX6 has been reported to be implicated in the development 
and progression of several human diseases, such as Alzheimer's 
disease (137), Parkinson's dementia (138), diabetes (139), 
cataractogenesis (140) and cancer. Concerning the neoplastic 
diseases, elevated levels of PRDX6 have been described 
in breast cancer (141), in malignant mesothelioma (67), in 
bladder cancer (61), in esophageal cancer (142), in lung (143), 
ovarian (87) and pancreas (144) cancer, in cancer of the 
gingivo-buccal area (145), and in lymphoma (146). Elevated 
expression levels of PRDX6 have been associated with a 
more invasive phenotype and metastatic potential of breast 
cancer (147), and with a worse prognosis of clinically localized 
prostate cancer following radical prostatectomy (148).
By contrast, studies performed using a thyroid proteomic 
approach have highlighted the reduction of PRDX6 in follicular 
adenomas (149), suggesting a possible role for this protein as a 
complementary marker to distinguish between different follic-
ular neoplasms. More recently, a marked reduction in PRDX6 
levels has been demonstrated in a cohort of PTCs (75). Taken 
together, all these studies have demonstrated that PRDX6 has 
a pro-tumorigenic function, promoting cell proliferation by its 
peroxidase activity, and facilitating invasiveness by means of 
its PLA2 activity (150).
To date, the association between PRDX6 single nucleotide 
polymorphisms (SNPs) and cancer has yet to be fully eluci-
dated. In esophageal cancer, no association was identified 
between the risk of cancer and clinicopathological character-
istics, including the tumor grade and stage, and the presence of 
SNPs (91). However, preliminary studies in breast cancer have 
demonstrated that the survival of carriers of the PRDX6 SNPs, 
rs4916362 and rs7314, was consistently less favorable (151).
5. PRDXs and chemoresistance
Cancer cells, compared with normal cells, have a high rate 
of ROS production as by-products of their metabolism (152), 
and to survive with this redox status, the levels of antioxidant 
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proteins, such as CAT, SOD, glutaredoxin and PRDXs, are 
increased (152-154). This unique capability of cancer cells may 
serve an important role also in the development of resistance 
to chemo- or radiotherapy, as these treatments are strongly 
dependent on ROS-induced cytotoxicity. A search of the 
literature demonstrates that increased levels of PRDXs are often 
associated with radioresistance or chemoresistance to numerous 
drugs. High levels of PRDX2 correlate with radioresistance in 
breast cancer and glioma cells (155), as well as with cisplatin 
chemoresistance in gastric cancer cell lines (156) and in 
human erythroleukemia K652 and human ovarian carcinoma 
SKOV-3 cells (157), since increased levels of this antioxidant 
inhibit apoptosis. Furthermore, in head-and-neck cancer and 
in gastric carcinoma cells, PRDX2‑specific antisense vectors 
restore the induction of pro-apoptotic pathways following 
radiation or cisplatin treatment, confirming the important 
role of PRDX2 in the resistance process (158). Several other 
types of cancer, including erythroleukemia, breast carcinoma 
and human ovarian carcinoma, develop cisplatin resistance 
through a significant increase in the levels of PRDX1, 
PRDX3 and PRDX6 (157,159). In addition, the upregulation 
of PRDX2 is also involved in the development of gefitinib 
resistance in a non-small cell lung carcinoma model, where 
it is responsible for the induction of tumor cell growth via 
activation of phosphorylated c-Jun N-terminal kinase (JNK) 
and the suppression of apoptosis signaling (160). In breast 
cancer cell lines, increased PRDX3 levels correlate with 
resistance to the chemotherapeutic drug, doxorubicin (161). 
PRDX3 controls the apoptotic signaling pathway through the 
regulation of cytochrome c release from the mitochondria, 
as well as through interaction with the complex of leucine 
zipper-bearing kinase (LZK) and IKB kinase (IKK). 
Therefore, it is conceivable that drugs targeting PRDX3 and 
the mitochondrion‑specific electron suppliers, Trx2, TrxR2 
and Srx, could represent a good strategy for improving the 
response to various chemotherapeutic agents, including 
cisplatin, paclitaxel and etoposide (162,163). Finally, there is 
evidence that PRDX5 is also involved in the chemoresistance 
to adriamycin, bleomycin, vinblastine and dacarbazine in 
patients affected with aggressive Hodgkin's lymphomas (127) 
and in vitro in the lung carcinoma U1810 cell line (164), always 
by inhibiting chemotherapeutic-induced apoptosis.
Chemoresistance is a complex phenomenon caused by 
multiple and heterogeneous mechanisms of action, which 
are orchestrated not only by the tumor microenvironment, 
but also by the biology of the tumor itself. The modulation 
of endogenous antioxidant levels may be a determining factor 
for the sensitivity of certain tumors to various chemothera-
peutic agents. In addition, it is important to highlight that the 
regulation of intracellular antioxidant concentration is a 
‘double‑edged sword’: On the one hand, enhanced antioxidant 
activity represents an advantageous protection of the cells from 
ROS, whereas, on the other hand, the depletion of antioxidants 
represents an important strategy to sensitize cancer cells to 
chemotherapy (chemosensitization) (50).
6. Conclusions
PRDXs serve a critical role in several physiological, as well as 
pathological, conditions involving redox signaling. Although 
their protective role in cardiovascular and neurological 
diseases is clear, their role in cancer remains controversial: 
Different PRDX isoforms may have a tumor-suppressor or an 
oncogenic role, depending on the cancer type. Considering 
the peroxidase-dependent and -independent secondary 
functions and the fine balance involved in the regulation of 
the oligomeric state and the function of the PRDX, more has 
been learnt about these antioxidants and their involvement 
in the control of cell growth and survival, particularly as a 
part of normal growth and development. To date, it remains 
to be clarified how the levels of peroxide and the peroxidases 
interplay, and how the regulatory behavior may change 
depending on the different developmental stages of the tissue, 
or on the disease states. Several studies have hypothesized that 
the ROS resistance of the cancer cells is sustained, at least 
in part, by overexpression of the PRDXs responsible for the 
antioxidant activity increase and/or the alteration in growth 
and activation of the death pathways (112,165). On the other 
hand, in certain cases PRDXs have been suggested to function 
as tumor preventers, rather than as tumor suppressors (166), 
in that, via detoxification of the ROS, they contribute to the 
maintenance of genomic integrity. In conclusion, in the future 
it will be crucial to clarify the exact role of PRDXs in cellular 
homeostasis, as well as in cancer development and drug 
resistance, in order to develop new target therapeutic strategies 
for cancer treatment or prevention.
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